Clinical Trial Update: Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate [Phase 3]

View source ↗

Summary

A Phase 3 trial update on discontinuing methotrexate in rheumatoid arthritis patients who achieve remission with upadacitinib plus methotrexate.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: Atsushi Kawakami | Conditions: Rheumatoid Arthritis, JAK Inhibitor | Phase 3 | Status: UNKNOWN